Abstract
We wanted to do a prospective open-label study to evaluate if ankylosing spondylitis (AS) patients in clinical remission with twice weekly etanercept (ETN) 25 mg therapy could be changed to weekly regimen or even to every other week regimen without increased dose for injection. Thirty-eight AS patients self-administered 25 mg of ETN (Wyett) subcutaneously. According to the protocol, patients who were in clinical partial remission with twice weekly ETN 25 mg at week 12 and 16 changed to a weekly regimen without a change of the dose. If clinical remission, despite the reduction of the dose, persists at week 24 and 28, patients changed to an every-other-week regimen, continuing with this administration schedule for the entire duration of the study if at week 36 and 46 clinical remission was maintained. At the end of the study, 18 patients (47 %) were still in remission, 4 (10 %) with a weekly regimen, and 14 (37 %) with an every-other-weekly regimen. Our study indicates that a consistent percentage of subjects with AS, treated with ETN 25 mg twice weekly, achieved clinical remission within the first 3 months of therapy, and also, a substantial percentage of these patients maintains the partial remission with an every other week regimen.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Braun J, Pham T, Sieper J et al (2003) International ASAS consensus statement for the use of anti-tumor necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62:817–824
Zochling J, van der Heijde D, Burgos-Vargas R et al (2006) ASAS/EURAL recommendations for the managementof ankylosing spondylitis. Ann Rheum Dis 65:442–452
Davis JC Jr, van der Heijde D, Braun J et al (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48:3230–3236
Van den Berg R, Stanislawska-Biernat E, Dèsirèe MFM, van der Heijde D (2011) Comparison of recommendations for the use of anti-tumour necrosis factor therapy in ankylosing spondylitis in 23 countries worldwide. Rheumatology 50:2270–2277
Navarro-Compan V, Moreira V, Ariza-Ariza R et al (2011) Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin Rheumatol 30:993–996
Lee SH, Lee YA, Hong SJ et al (2008) Etanercept 25mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients. Clin Rheumatol 27:179–181
Moghimi J, Sheikhvatan M, Semvani V. The use of low dose etanercept as an alternative therapy for treatment of ankylosing spondylitis: a case series. Rheumatol Int doi: 10.1007/s00296-011-1920-0
Brandt J, Listing J, Haibel H et al (2005) Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology 44:342–348
Foster C, Tufail F, Waheed N, Chu D, Miserochi E, Baltatzis S et al (2003) Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 121:437–440
Rosenbaum J (2004) Effect of etanercept on iritis in patients with ankylosing spondylitis. Arthritis Rheum 50:3736–3737
van der Horst-Bruinsma IE, Nurmohamed MT (2012) Management and evaluation of extra-articular manifestations in spondyloarthritis. Ther Adv Musculoskelet Dis 4(6):413–422
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
De Stefano, R., Frati, E., De Quattro, D. et al. Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients. Clin Rheumatol 33, 707–711 (2014). https://doi.org/10.1007/s10067-013-2372-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-013-2372-6